MARKET

INFI

INFI

Infinity Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.630
+0.050
+1.40%
Closed 19:38 09/22 EDT
OPEN
3.580
PREV CLOSE
3.580
HIGH
3.650
LOW
3.530
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
5.98
52 WEEK LOW
1.000
MARKET CAP
322.05M
P/E (TTM)
-6.0149
1D
5D
1M
3M
1Y
5Y
Infinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune...
Business Wire · 09/13 12:35
Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D., to Its Board of Directors
--- Brian Schwartz, M.D., transitioning from Consulting Chief Physician to Infinity's Board of Directors -
Business Wire · 09/07 11:35
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
CAMBRIDGE, Mass., September 02, 2021--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fu...
Business Wire · 09/02 12:35
Callan Capital, LLC Buys BTC iShares MSCI Emerging Markets Multifactor ETF, Invesco Russell ...
GuruFocus News · 08/23 16:38
Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options
Zacks.com · 08/23 12:32
Infinity Stock Could More Than Double From Here, Says Analyst
If there was a competition for the stock market’s most volatile stock, it’s likely the recent gyrations of Infinity Pharmaceuticals (INFI) will make it one of the front runners. The past week has seen huge swings in both directions, making it hard to know ...
TipRanks · 08/04 16:00
Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., August 03, 2021--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogram...
Business Wire · 08/03 12:00
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.
Benzinga · 08/03 08:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INFI. Analyze the recent business situations of Infinity Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INFI stock price target is 9.29 with a high estimate of 14.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 116
Institutional Holdings: 44.39M
% Owned: 50.03%
Shares Outstanding: 88.72M
TypeInstitutionsShares
Increased
22
9.05M
New
33
3.54M
Decreased
24
6.07M
Sold Out
18
4.61M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Chief Executive Officer/Director
Adelene Perkins
President/Treasurer
Lawrence Bloch
Senior Vice President/Secretary
Seth Tasker
Chief Scientific Officer
Stephane Peluso
Other
Robert Ilaria
Lead Director/Independent Director
Norman Selby
Director
Samuel Agresta
Director
Brian Schwartz
Independent Director
David Beier
Independent Director
Anthony Evnin
Independent Director
Richard Gaynor
No Data
About INFI
Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.

Webull offers kinds of Infinity Pharmaceuticals Inc. stock information, including NASDAQ:INFI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INFI stock methods without spending real money on the virtual paper trading platform.